Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.36)
# 1,226
Out of 4,408 analysts
500
Total ratings
44.8%
Success rate
8.1%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Reiterated: Buy | $24 → $29 | $12.55 | +131.08% | 17 | Jun 11, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $21 | $12.14 | +72.98% | 3 | May 28, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $27 | $2.48 | +988.71% | 20 | May 19, 2026 | |
| BIIB Biogen | Reiterated: Buy | $245 | $198.64 | +23.34% | 82 | May 15, 2026 | |
| CLNN Clene | Reiterated: Buy | $50 | $5.77 | +766.55% | 12 | May 15, 2026 | |
| GHRS GH Research | Reiterated: Buy | $39 | $20.37 | +91.46% | 17 | May 15, 2026 | |
| MPLT MapLight Therapeutics | Reiterated: Buy | $35 | $27.96 | +25.18% | 2 | May 15, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $18 | $11.79 | +52.67% | 22 | May 14, 2026 | |
| ATAI AtaiBeckley | Reiterated: Buy | $15 | $3.84 | +290.63% | 21 | May 13, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $3.63 | +230.58% | 38 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $23.77 | +59.87% | 14 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $30.00 | +100.00% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 | $21.27 | +50.48% | 51 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $159.51 | +25.38% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $1.78 | +855.06% | 11 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $4.25 | +958.82% | 22 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $1.16 | +1,451.72% | 55 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $2.67 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $0.931 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $33.54 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $33.69 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $16.32 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $16.24 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $10.70 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $195.24 | $6.98 | n/a | 7 | Dec 18, 2015 |
Zevra Therapeutics
Jun 11, 2026
Reiterated: Buy
Price Target: $24 → $29
Current: $12.55
Upside: +131.08%
Biohaven
May 28, 2026
Reiterated: Buy
Price Target: $21
Current: $12.14
Upside: +72.98%
CervoMed
May 19, 2026
Reiterated: Buy
Price Target: $27
Current: $2.48
Upside: +988.71%
Biogen
May 15, 2026
Reiterated: Buy
Price Target: $245
Current: $198.64
Upside: +23.34%
Clene
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $5.77
Upside: +766.55%
GH Research
May 15, 2026
Reiterated: Buy
Price Target: $39
Current: $20.37
Upside: +91.46%
MapLight Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: $35
Current: $27.96
Upside: +25.18%
COMPASS Pathways
May 14, 2026
Reiterated: Buy
Price Target: $18
Current: $11.79
Upside: +52.67%
AtaiBeckley
May 13, 2026
Reiterated: Buy
Price Target: $15
Current: $3.84
Upside: +290.63%
Voyager Therapeutics
May 11, 2026
Reiterated: Buy
Price Target: $12
Current: $3.63
Upside: +230.58%
May 8, 2026
Reiterated: Buy
Price Target: $38
Current: $23.77
Upside: +59.87%
May 8, 2026
Maintained: Buy
Price Target: $60
Current: $30.00
Upside: +100.00%
May 6, 2026
Maintained: Buy
Price Target: $32
Current: $21.27
Upside: +50.48%
May 6, 2026
Reiterated: Buy
Price Target: $200
Current: $159.51
Upside: +25.38%
Apr 14, 2026
Reiterated: Buy
Price Target: $17
Current: $1.78
Upside: +855.06%
Mar 6, 2026
Reiterated: Buy
Price Target: $45
Current: $4.25
Upside: +958.82%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $1.16
Upside: +1,451.72%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $2.67
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $0.931
Upside: n/a
Apr 9, 2018
Maintained: Hold
Price Target: n/a
Current: $33.54
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $33.69
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $16.32
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $16.24
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $10.70
Upside: n/a
Dec 18, 2015
Maintained: Buy
Price Target: $195.24
Current: $6.98
Upside: n/a